Interventional Cardiology
CAD diagnosis, treatment, and outcomes
Also called CAD, coronary disease, ischemic heart disease
Sources: 12 new papers · 5 key papers · updated Oct 20, 2026
What 6 experts said about this trial's result
Expert labels are toward ISCHEMIA-EXTEND's result, from named public quotes (n=6). As of Nov 13, 2026.
Unverified · drafted by AI from the sources cited below
Coronary artery disease involves pathological processes of coronary arteries derived from congenital abnormalities, atherosclerotic, or non-atherosclerotic causes.1
Elevated lipoprotein(a) and coronary artery calcium scores categorized as 0, 1-99, and ≥100 are independently associated with an increased risk of cardiovascular disease during 13.2 years of follow-up.1 Additionally, human epididymis protein 4 is a prognostic biomarker for major adverse cardiovascular events over a 10-year period when utilizing a cut-off of 8.0 ng/mL.2 Among young patients presenting with acute myocardial infarction, 10%-20% have nonobstructive coronary arteries.3
Percutaneous coronary intervention is a treatment for coronary artery disease, and intravascular imaging with optical coherence tomography or intravascular ultrasound can guide the procedure.1 In a trial of 2008 patients, primary end point events at 1 year occurred in 2.5% of the optical coherence tomography group and 3.1% of the intravascular ultrasound group.1 Treatment strategy can also be guided by a fractional flow reserve of ≤0.80 in stenotic ≥50% lesions, as evaluated in a trial of 927 patients with multivessel disease.2 Furthermore, quantitative flow ratio has been assessed for guiding intervention in lesions with a diameter stenosis of 50-90% in vessels of at least 2·5 mm.3
FDA approvals, label changes, device decisions and recalls on Coronary artery disease from the last three months.
Applicant: Elucid Bioimaging, Inc.. Clearance: Traditional. Cardiovascular
The FDA has issued a Premarket Approval (PMA) notice for a drug-eluting percutaneous transluminal coronary angioplasty (PTCA) catheter developed by MedAlliance, LLC. The cardiovascular device is indicated for interventional coronary procedures.
Association between periodontitis and coronary plaque composition: can early periodontal treatment influence coronary artery disease progression? A study protocol for a prospective, randomized controlled trial
BMC Oral Health — Weichsel L — Nov 2026
Volumetric Quantification of Retinal Ischemic Perivascular Lesions (RIPLs) in Coronary Artery Disease
Investigative Ophthalmology & Visual Science — Jeremic N — Nov 2026
TCT Discussion
U Miami Cardiovascular — Tue, Nov 10, 7:00 AM EST — 2 attended
CCU #bruinhearts Journal Club OPTIMAL
UCLA #bruinhearts — Tue, Sep 22, 3:00 PM EDT — 1 attended
#bruinhearts CCU Journal Club: ISCHEMIA trial
UCLA #bruinhearts — Tue, Aug 25, 3:00 PM EDT — 3 attended
PRO-TAVI: The Heart of the Matter
OPCI Journal Club — Fri, Jul 24, 12:00 PM EDT
Sessions from public communities on Synapse. RSVP to join the live discussion.
Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial
The Lancet
449 citations · 2021 · among the most cited on Coronary artery disease
Optical Coherence Tomography–Guided or Intravascular Ultrasound–Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial
Circulation — Kang D
181 citations · 2023 · among the most cited on Coronary artery disease
Causes, Angiographic Characteristics, and Management of Premature Myocardial Infarction
Journal of the American College of Cardiology — Rallidis L
137 citations · 2022 · among the most cited on Coronary artery disease
Fractional Flow Reserve to Guide Treatment of Patients With Multivessel Coronary Artery Disease
Journal of the American College of Cardiology — Rioufol G
115 citations · 2021 · among the most cited on Coronary artery disease
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.
Current Atherosclerosis Reports — Steuerwald M — Nov 2026
“The OPTIMAL trial demonstrated no significant clinical benefit for routine IVUS guidance over angiography alone in unprotected left main coronary disease.”
“Trial findings reflect a population with modest coronary disease (median SYNTAX score of 10), leaving the management of complex bifurcations and severe stenoses open to clinician judgment.”